Advanced in Graft Versus Host Disease (GvHD)
Advanced in Graft Versus Host Disease (GvHD)
3800 Reservoir Rd Nw, 
Washington, DC 

Overview

Corina Gonzalez is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Gonzalez is rated as an Advanced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Graft Versus Host Disease (GvHD), Severe Combined Immunodeficiency (SCID), Chronic Graft Versus Host Disease (cGvHD), X-Linked Severe Combined Immunodeficiency, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Graft Versus Host Disease (GvHD).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in DC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

3800 Reservoir Rd Nw, Washington, DC 20007

Additional Areas of Focus

Dr. Gonzalez has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Umbrella Long-Term Follow-Up Protocol
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Renal Tumors Classification, Biology, and Banking Study
View 11 Less Clinical Trials
Similar Doctors
Heather Symons
Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology
Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology

Johns Hopkins Children's Center

Baltimore, MD 
 (37.1 miles away)
Languages Spoken:
English

"In her first decade as a pediatric oncologist, Dr. Symons already has shown an impressive ability to juggle multiple research projects, in addition to caring for patients. One of Dr. Symons' research pursuits focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. The basis of her work stems from the theory that cancer patients' immune systems should recognize tumor cells as foreign and destroy them. This doesn't happen, theorizes Dr. Symons, because the immune system attacks only those cells it perceives as dangerous—not cancer cells, which it sees simply as foreign. That's where her research comes into play. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will ""awaken"" patients' immune systems to the danger of existing cancer cells and, in turn, elicit an immune response. In a separate yet equally compelling research endeavor, Dr. Symons is working to increase the availability of donors for children whose cancer requires bone marrow transplants (BMTs) as a potentially lifesaving treatment. ""It can be challenging to find a 'matched' donor,"" says Dr. Symons, who explains that only about 40 percent of patients who require a BMT find a matched donor. ""Sometimes, we don't have the benefit of time, because remissions can be short-lived. But almost all patients have a half-matched donor: a parent, sibling, or child,"" adds Dr. Symons, who is examining ways to reduce BMT-related complications ordinarily associated with half-matched donors after ablative (high dose) chemotherapy. ""Like anything else that's new, it will take some time to prove that this is a feasible option that's safe,"" she says. But she's optimistic. ""It has the potential to revolutionize BMT."" Dr. Symons knows it's worth the wait. ""Seeing the research I do in the lab translate into clinical trials, then seeing patients in these trials survive long term, is incredibly rewarding,"" she says.". Dr. Symons is rated as an Advanced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, Leukemia, and Bone Marrow Transplant.

Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology
Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology
111 Michigan Ave Nw, 5th Floor Main, Suite 5207, 
Washington, DC 
 (3.4 miles away)
Languages Spoken:
English

Catherine Bollard is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Bollard is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Leukemia, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Transplant.

Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology
Advanced in Graft Versus Host Disease (GvHD)
Pediatric Hematology Oncology
111 Michigan Ave Nw, 
Washington, DC 
 (3.4 miles away)
Languages Spoken:
English

Allistair Abraham is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Abraham is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gonzalez's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile